Ovid Therapeutics Inc. (OVID) by event type
OVID moves most on analyst upgrades — a median of -0.90% at 30 minutes across 11 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the OVID overview →
How OVID reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,577 of 2,717 | 11 | -0.90% | 46% | -1.15% |
| Coverage initiations 2,035 of 2,283 | 29 | -0.75% | 31% | +1.16% |
| Rating reiterations 505 of 3,522 | 37 | +0.18% | 51% | -0.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how OVID usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Coverage initiations → · Rating reiterations → · OVID overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Lixte Biotechnology Holdings, Inc. (LIXT) | 239 | 0.00% | 48% |
| MeiraGTx Holdings plc - Ordinary Shares (MGTX) | 239 | -0.10% | 46% |
| Cyclacel Pharmaceuticals, Inc. (CYCC) | 238 | -0.21% | 42% |
| RESTORBIO (TORC) | 238 | -0.17% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.